TY  - JOUR

T1  - The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.

JO  - Eur J Cancer

PY  - 2007/11/01

AU  - Tappenden P

AU  - Jones R

AU  - Paisley S

AU  - Carroll C

ED  - 

DO  - DOI: 10.1016/j.ejca.2007.08.017

VL  - 43

IS  - 17

SP  - 2487

EP  - 2494

Y2  - 2024/09/20

ER  -